| P2093 | author name string | Jian Zhang | |
| | Kai Wang | |
| | Lu Cai | |
| | Jian Sun | |
| | Xuemian Lu | |
| | Wenya Weng | |
| P2860 | cites work | Fibroblast growth factor 21 protects against high glucose induced cellular damage and dysfunction of endothelial nitric-oxide synthase in endothelial cells | Q46845830 |
| | Fibroblast growth factor 21 protects against acetaminophen-induced hepatotoxicity by potentiating peroxisome proliferator-activated receptor coactivator protein-1α-mediated antioxidant capacity in mice | Q46924515 |
| | Suppression of GLUT1; a new strategy to prevent diabetic complications | Q47596197 |
| | Fibroblast growth factor 21 decreases after liver fat reduction via growth hormone augmentation | Q47795127 |
| | FGF21 Attenuates High-Fat Diet-Induced Cognitive Impairment via Metabolic Regulation and Anti-inflammation of Obese Mice | Q47919673 |
| | Serum fibroblast growth factor-21 levels are associated with carotid atherosclerosis independent of established cardiovascular risk factors. | Q47931952 |
| | FGF21 maintains glucose homeostasis by mediating the cross talk between liver and brain during prolonged fasting | Q48659709 |
| | Fibroblast growth factor 21: a novel biomarker for human muscle-manifesting mitochondrial disorders. | Q50894988 |
| | G-protein-coupled bile acid receptor plays a key role in bile acid metabolism and fasting-induced hepatic steatosis in mice. | Q51282593 |
| | Fibroblast growth factor 21 prevents glycemic deterioration in insulin deficient mouse models of diabetes. | Q51300354 |
| | Dynamic change of serum FGF21 levels in response to glucose challenge in human. | Q51357652 |
| | Direct effects of FGF21 on glucose uptake in human skeletal muscle: implications for type 2 diabetes and obesity. | Q51379603 |
| | Molecular cloning and expression analyses of mouse betaklotho, which encodes a novel Klotho family protein. | Q52163868 |
| | Up-regulation of Nrf2 is involved in FGF21-mediated fenofibrate protection against type 1 diabetic nephropathy. | Q53183054 |
| | Forced expression of hepatocyte-specific fibroblast growth factor 21 delays initiation of chemically induced hepatocarcinogenesis. | Q53342644 |
| | Long-acting hypoglycemic effects of PEGylated FGF21 and insulin glargine in mice with type 1 diabetes. | Q53676267 |
| | Fibroblast growth factor 21 protects the heart from apoptosis in a diabetic mouse model via extracellular signal-regulated kinase 1/2-dependent signalling pathway. | Q54268091 |
| | [Therapeutic effect of fibroblast growth factor 21 on hypertension induced by insulin resistance]. | Q54412488 |
| | Brown Adipose Tissue Metabolism in Streptozotocin-Diabetic Rats* | Q72789808 |
| | Leukocyte-endothelial cell interactions in nitric oxide synthase-deficient mice | Q77855505 |
| | Distinct changes in serum fibroblast growth factor 21 levels in different subtypes of diabetes | Q82108485 |
| | Effects of metformin on plasma concentrations of glucose and mannose, G6Pase and PEPCK activity, and mRNA expression in the liver and kidney of chickens | Q83858337 |
| | Basal and postprandial change in serum fibroblast growth factor-21 concentration in type 1 diabetic mellitus and in healthy controls | Q85262030 |
| | Nrf2 induces fibroblast growth factor 21 in diabetic mice | Q85654740 |
| | Fibroblast growth factor 21 analogue LY2405319 lowers blood glucose in streptozotocin-induced insulin-deficient diabetic mice by restoring brown adipose tissue function | Q85893184 |
| | The relationship of fibroblast growth factor 21 with cardiovascular outcome events in the Fenofibrate Intervention and Event Lowering in Diabetes study | Q86057048 |
| | betaKlotho is required for fibroblast growth factor (FGF) 21 signaling through FGF receptor (FGFR) 1c and FGFR3c | Q24306279 |
| | Tissue-specific expression of betaKlotho and fibroblast growth factor (FGF) receptor isoforms determines metabolic activity of FGF19 and FGF21 | Q24318639 |
| | FGF21 N- and C-termini play different roles in receptor interaction and activation | Q24322074 |
| | FGF-21 as a novel metabolic regulator | Q24523933 |
| | Obesity Is a Fibroblast Growth Factor 21 (FGF21)-Resistant State | Q24625976 |
| | BetaKlotho is required for metabolic activity of fibroblast growth factor 21 | Q24681531 |
| | Molecular insights into the klotho-dependent, endocrine mode of action of fibroblast growth factor 19 subfamily members | Q24683254 |
| | The interplay of autoimmunity and insulin resistance in type 1 diabetes | Q26823862 |
| | Approaches to prevention of cardiovascular complications and events in diabetes mellitus | Q28209964 |
| | Actions and mode of actions of FGF19 subfamily members | Q28249481 |
| | A better anti-diabetic recombinant human fibroblast growth factor 21 (rhFGF21) modified with polyethylene glycol | Q28478454 |
| | FGF21 requires βklotho to act in vivo | Q28485347 |
| | Pancreatic beta-cell-specific targeted disruption of glucokinase gene. Diabetes mellitus due to defective insulin secretion to glucose | Q28507345 |
| | Glucagon increases circulating fibroblast growth factor 21 independently of endogenous insulin levels: a novel mechanism of glucagon-stimulated lipolysis? | Q28571194 |
| | Fibroblast growth factor 21 as a possible endogenous factor inhibits apoptosis in cardiac endothelial cells | Q28580994 |
| | Hepatic fibroblast growth factor 21 is regulated by PPARalpha and is a key mediator of hepatic lipid metabolism in ketotic states | Q29615208 |
| | Fibroblast growth factor signalling: from development to cancer | Q29616827 |
| | Fibroblast growth factor 21, the endocrine FGF pathway and novel treatments for metabolic syndrome. | Q30355232 |
| | Elevated serum fibroblast growth factor 21 is associated with hypertension in community-dwelling adults | Q33764675 |
| | Serum levels of FGF-21 are increased in coronary heart disease patients and are independently associated with adverse lipid profile | Q33785827 |
| | Fibroblast growth factor 21 action in the brain increases energy expenditure and insulin sensitivity in obese rats | Q33930333 |
| | Paradoxical regulation of human FGF21 by both fasting and feeding signals: is FGF21 a nutritional adaptation factor? | Q33988652 |
| | Effects of short-term continuous subcutaneous insulin infusion on fasting plasma fibroblast growth factor-21 levels in patients with newly diagnosed type 2 diabetes mellitus | Q34064416 |
| | Renal filtration, transport, and metabolism of low-molecular-weight proteins: A review | Q34195953 |
| | Research resource: Comprehensive expression atlas of the fibroblast growth factor system in adult mouse. | Q34197301 |
| | High levels of glucose-6-phosphatase gene and protein expression reflect an adaptive response in proliferating liver and diabetes | Q34202975 |
| | Glucagon and lipid interactions in the regulation of hepatic AMPK signaling and expression of PPARα and FGF21 transcripts in vivo | Q34215218 |
| | Roles of FGFs as Adipokines in Adipose Tissue Development, Remodeling, and Metabolism | Q34408855 |
| | Circulating FGF21 is liver derived and enhances glucose uptake during refeeding and overfeeding. | Q34428501 |
| | The metabolic state of diabetic monkeys is regulated by fibroblast growth factor-21. | Q34577053 |
| | Fibroblast growth factor 21 corrects obesity in mice | Q34805555 |
| | The pathology of atherosclerosis: plaque development and plaque responses to medical treatment | Q34911035 |
| | Attenuation of hyperlipidemia- and diabetes-induced early-stage apoptosis and late-stage renal dysfunction via administration of fibroblast growth factor-21 is associated with suppression of renal inflammation | Q35070137 |
| | High plasma level of fibroblast growth factor 21 is an Independent predictor of type 2 diabetes: a 5.4-year population-based prospective study in Chinese subjects | Q35179850 |
| | Nrf2 represses FGF21 during long-term high-fat diet-induced obesity in mice | Q35227185 |
| | Growth hormone induces hepatic production of fibroblast growth factor 21 through a mechanism dependent on lipolysis in adipocytes | Q35266423 |
| | Fibroblast growth factor 21 (FGF21) in human cerebrospinal fluid: relationship with plasma FGF21 and body adiposity | Q35405521 |
| | Fibroblast growth factor 21 prevents atherosclerosis by suppression of hepatic sterol regulatory element-binding protein-2 and induction of adiponectin in mice. | Q35648897 |
| | FGF21 regulates PGC-1α and browning of white adipose tissues in adaptive thermogenesis | Q35755169 |
| | Heart CD36 expression is increased in murine models of diabetes and in mice fed a high fat diet | Q35762949 |
| | Fibroblast growth factor 21 deletion aggravates diabetes-induced pathogenic changes in the aorta in type 1 diabetic mice | Q35794417 |
| | FGF21 deletion exacerbates diabetic cardiomyopathy by aggravating cardiac lipid accumulation | Q35879505 |
| | Sequential intensification of metformin treatment in type 2 diabetes with liraglutide followed by randomized addition of basal insulin prompted by A1C targets | Q36047167 |
| | Fibroblast growth factor 21 limits lipotoxicity by promoting hepatic fatty acid activation in mice on methionine and choline-deficient diets | Q36061647 |
| | Pharmacokinetics and pharmacodynamics of PF-05231023, a novel long-acting FGF21 mimetic, in a first-in-human study | Q36243635 |
| | βKlotho is required for fibroblast growth factor 21 effects on growth and metabolism | Q36248720 |
| | Long-chain fatty acid uptake and FAT/CD36 translocation in heart and skeletal muscle | Q36274041 |
| | FGF23 is a hormone-regulating phosphate metabolism--unique biological characteristics of FGF23. | Q36727664 |
| | An FGF21-adiponectin-ceramide axis controls energy expenditure and insulin action in mice | Q36886578 |
| | Increased fibroblast growth factor 21 in obesity and nonalcoholic fatty liver disease | Q36889026 |
| | Impaired Mitochondrial Fat Oxidation Induces FGF21 in Muscle | Q36936246 |
| | FGF21 is an Akt-regulated myokine | Q37017459 |
| | Additive relationship between serum fibroblast growth factor 21 level and coronary artery disease | Q37153759 |
| | Endocrine protection of ischemic myocardium by FGF21 from the liver and adipose tissue | Q37199307 |
| | Free fatty acids link metabolism and regulation of the insulin-sensitizing fibroblast growth factor-21. | Q37236253 |
| | High glucose represses β-klotho expression and impairs fibroblast growth factor 21 action in mouse pancreatic islets: involvement of peroxisome proliferator-activated receptor γ signaling | Q37251086 |
| | Hormone-like (endocrine) Fgfs: their evolutionary history and roles in development, metabolism, and disease | Q37781747 |
| | Effects of polyunsaturated fatty acid consumption in diabetic nephropathy | Q37816963 |
| | Fibroblast growth factor 21 as an emerging metabolic regulator: clinical perspectives. | Q38058339 |
| | Significant gender difference in serum levels of fibroblast growth factor 21 in Danish children and adolescents | Q38216640 |
| | Development of a novel long-acting antidiabetic FGF21 mimetic by targeted conjugation to a scaffold antibody | Q38315161 |
| | Lack of overt FGF21 resistance in two mouse models of obesity and insulin resistance | Q38330457 |
| | Acute glucose-lowering and insulin-sensitizing action of FGF21 in insulin-resistant mouse models--association with liver and adipose tissue effects | Q38351110 |
| | FGF21 improves glucose homeostasis in an obese diabetes-prone mouse model independent of body fat changes | Q38645276 |
| | Fatty liver and FGF21 physiology | Q38678326 |
| | Fibroblast Growth Factor 21 As an Emerging Therapeutic Target for Type 2 Diabetes Mellitus | Q38794405 |
| | Fenofibrate increases cardiac autophagy via FGF21/SIRT1 and prevents fibrosis and inflammation in the hearts of Type 1 diabetic mice | Q38800859 |
| | FGF21 treatment ameliorates alcoholic fatty liver through activation of AMPK-SIRT1 pathway | Q38943985 |
| | Therapeutics Targeting FGF Signaling Network in Human Diseases | Q39043236 |
| | The role of fibroblast growth factor 21 in atherosclerosis. | Q39052639 |
| | Differential specificity of endocrine FGF19 and FGF21 to FGFR1 and FGFR4 in complex with KLB. | Q39374896 |
| | Inhibition of inflammation by pentosan polysulfate impedes the development and progression of severe diabetic nephropathy in aging C57B6 mice | Q39496640 |
| | Fibroblast growth factor-21 improves pancreatic beta-cell function and survival by activation of extracellular signal-regulated kinase 1/2 and Akt signaling pathways. | Q40239037 |
| | Circulating fibroblast growth factor-21 is elevated in impaired glucose tolerance and type 2 diabetes and correlates with muscle and hepatic insulin resistance. | Q41760918 |
| | Targeting hepatic glucokinase in type 2 diabetes: weighing the benefits and risks | Q41866371 |
| | The breadth of FGF21's metabolic actions are governed by FGFR1 in adipose tissue | Q41912342 |
| | FGF-21 enhances islet engraftment in mouse syngeneic islet transplantation model | Q42552463 |
| | Protective effect of FGF21 on type 1 diabetes-induced testicular apoptotic cell death probably via both mitochondrial- and endoplasmic reticulum stress-dependent pathways in the mouse model | Q42712480 |
| | Resveratrol prevents renal lipotoxicity and inhibits mesangial cell glucotoxicity in a manner dependent on the AMPK-SIRT1-PGC1α axis in db/db mice | Q42715172 |
| | Adipose fibroblast growth factor 21 is up-regulated by peroxisome proliferator-activated receptor gamma and altered metabolic states. | Q42813296 |
| | FGF-21/FGF-21 receptor interaction and activation is determined by betaKlotho | Q42819634 |
| | Increased serum FGF21 levels in patients with nonalcoholic fatty liver disease. | Q42972684 |
| | Physiological modulation of circulating FGF21: relevance of free fatty acids and insulin. | Q43083741 |
| | Serum concentrations and tissue expression of a novel endocrine regulator fibroblast growth factor-21 in patients with type 2 diabetes and obesity. | Q43287114 |
| | Fibroblast growth factor 21 reduces the severity of cerulein-induced pancreatitis in mice | Q43296116 |
| | Fibroblast growth factor 21 (FGF-21) and its relation to obesity, metabolic syndrome, and nonalcoholic fatty liver in children: a longitudinal analysis | Q43577294 |
| | Effects of fibroblast growth factor 21 on cell damage in vitro and atherosclerosis in vivo | Q43639041 |
| | Adiponectin mediates the metabolic effects of FGF21 on glucose homeostasis and insulin sensitivity in mice | Q44504595 |
| | The effects of LY2405319, an FGF21 analog, in obese human subjects with type 2 diabetes | Q45834496 |
| | Enhancement of the pharmacological efficacy of FGF-21 by genetic modification and PEGylation | Q46103178 |
| | Fibroblast growth factor 21 protects against cardiac hypertrophy in mice. | Q46527697 |
| | Fibroblast growth factor 21 improves insulin resistance and ameliorates renal injury in db/db mice | Q46640076 |
| | Fibroblast growth factor (FGF21) protects mouse liver against D-galactose-induced oxidative stress and apoptosis via activating Nrf2 and PI3K/Akt pathways | Q46769752 |
| | Serum FGF21 levels are increased in obesity and are independently associated with the metabolic syndrome in humans | Q46770146 |
| P275 | copyright license | Creative Commons Attribution-NonCommercial | Q6936496 |
| P433 | issue | 9 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | type-1 diabetes | Q124407 |
| | peptide | Q172847 |
| P304 | page(s) | 1000-1011 | |
| P577 | publication date | 2018-06-02 | |
| P1433 | published in | International Journal of Biological Sciences | Q6051326 |
| P1476 | title | The role of FGF21 in type 1 diabetes and its complications | |
| P478 | volume | 14 | |